Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | RORC | P51449 | 8/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.38 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18093442 | 1.00 | NR1H2 (0.44) | NR1H2RORCGPR119HDAC1HDAC2 | |
| SCHEMBL18093440 | 1.00 | NR1H2 (0.44) | NR1H2RORCGPR119HDAC1HDAC2 | |
| SCHEMBL18093463 | 0.84 | NR1H2 (0.41) | NR1H2RORCGPR119HDAC1HDAC2 | |
| SCHEMBL18093462 | 0.84 | NR1H2 (0.41) | NR1H2RORCGPR119HDAC1HDAC2 | |
| SCHEMBL18093461 | 0.84 | NR1H2 (0.41) | NR1H2RORCGPR119HDAC1HDAC2 | |
| SCHEMBL18093423 | 0.82 | MAPT (0.50) | RORCKDM1A | |
| SCHEMBL18091499 | 0.82 | MAPT (0.50) | RORCKDM1A | |
| SCHEMBL18091500 | 0.82 | MAPT (0.50) | RORCKDM1A | |
| SCHEMBL18091498 | 0.82 | MAPT (0.50) | RORCKDM1A | |
| SCHEMBL18091569 | 0.82 | NPY1R (0.41) | PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663463-B2 | 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| US-20160280645-A1 | NOVEL 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSE | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280645-A1 | NOVEL 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSE | OPRM1, OPRD1, OPRK1 | NR1H2 97/4885RORC 237/4885GPR119 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.